000301714 001__ 301714
000301714 005__ 20250627115808.0
000301714 0247_ $$2doi$$a10.1007/s00117-025-01459-5
000301714 0247_ $$2pmid$$apmid:40434719
000301714 0247_ $$2ISSN$$a2731-7048
000301714 0247_ $$2ISSN$$a0033-832X
000301714 0247_ $$2ISSN$$a1432-2102
000301714 0247_ $$2ISSN$$a2731-7056
000301714 037__ $$aDKFZ-2025-01106
000301714 041__ $$aGerman
000301714 082__ $$a610
000301714 1001_ $$0P:(DE-He78)2af28acfaad8f466abb166306f9597bd$$aNeelsen, Christian Jan Oliver$$b0$$eFirst author$$udkfz
000301714 245__ $$aStaging and treatment response assessment with radiological and nuclear medicine approaches for non-Hodgkin lymphomas.[Staging und Therapieansprechen mit radiologischen und nuklearmedizinischen Verfahren bei Non-Hodgkin-Lymphomen (NHL)].
000301714 260__ $$a[Berlin]$$bSpringer Medizin Verlag GmbH$$c2025
000301714 3367_ $$2DRIVER$$aarticle
000301714 3367_ $$2DataCite$$aOutput Types/Journal article
000301714 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1751018257_5832$$xReview Article
000301714 3367_ $$2BibTeX$$aARTICLE
000301714 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301714 3367_ $$00$$2EndNote$$aJournal Article
000301714 500__ $$a#EA:E010#LA:E060# / Volume 65, pages 508–517, (2025)
000301714 520__ $$aNon-Hodgkin lymphomas (NHL) represent a heterogeneous group of malignant diseases in which the choice of imaging modality and response criteria strongly depends on histology and clinical context. Selecting the appropriate method is essential for individualized treatment planning.According to the Lugano classification, 18F‑fluorodeoxyglucose positron emission tomography/computed tomography (18F‑FDG PET/CT) is the reference standard for staging and response assessment in 18F-FDG-avid NHL. For other lymphoma subtypes with low or variable 18F-FDG avidity, or in cases where reimbursement by statutory health insurance (GKV) is lacking, contrast-enhanced CT is typically used.This article discusses the new classification systems Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) and Response Evaluation Criteria in Lymphoma (RECIL), as well as specific features of certain lymphoma subtypes and novel imaging approaches such as whole-body MRI and innovative PET tracers.This narrative review does not include a systematic evaluation of sensitivity or specificity data.In 18F-FDG-avid lymphomas 18F‑FDG PET/CT remains the gold standard for precise staging and response assessment.Imaging is essential for tailored therapy planning and monitoring in NHL. As most NHL subtypes are 18FDG-avid, PET/CT is the reference standard. However, contrast-enhanced CT continues to play a significant role, particularly in Germany. New PET tracers and whole-body MRI offer promising approaches but require further studies and standardization.
000301714 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000301714 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301714 650_7 $$2Other$$aComputed tomography
000301714 650_7 $$2Other$$aDiffuse large B‑cell lymphoma
000301714 650_7 $$2Other$$aPositron emission tomography
000301714 650_7 $$2Other$$aResponse Evaluation Criteria in Lymphoma
000301714 650_7 $$2Other$$aResponse assessment
000301714 7001_ $$0P:(DE-He78)496f1cb8c66dea4b539e53c1971f2473$$aMohammad, Ahmad$$b1$$eFirst author$$udkfz
000301714 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b2$$udkfz
000301714 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b3$$udkfz
000301714 7001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b4$$eLast author$$udkfz
000301714 773__ $$0PERI:(DE-600)3120921-X$$a10.1007/s00117-025-01459-5$$p508–517$$tDie Radiologie$$v65$$x2731-7048$$y2025
000301714 909CO $$ooai:inrepo02.dkfz.de:301714$$pVDB
000301714 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2af28acfaad8f466abb166306f9597bd$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301714 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)496f1cb8c66dea4b539e53c1971f2473$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000301714 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000301714 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000301714 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000301714 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000301714 9141_ $$y2025
000301714 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-18$$wger
000301714 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-18$$wger
000301714 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOLOGIE : 2022$$d2024-12-18
000301714 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000301714 9202_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000301714 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000301714 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x1
000301714 9200_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000301714 980__ $$ajournal
000301714 980__ $$aVDB
000301714 980__ $$aI:(DE-He78)E010-20160331
000301714 980__ $$aI:(DE-He78)E060-20160331
000301714 980__ $$aUNRESTRICTED